Nicotine
C₁₀H₁₄N₂
Also known as: (S)-Nicotine, (S)-3-(1-Methylpyrrolidin-2-yl)pyridine, Nicotiana alkaloid
Disclaimer: This information is for educational purposes only and is not intended as medical advice. Consult a healthcare professional before starting any supplement regimen.
Molecular Profile
C₁₀H₁₄N₂
162.23 g/mol
(S)-3-(1-Methylpyrrolidin-2-yl)pyridine
54-11-5
Overview
Nicotine is a plant alkaloid that occurs naturally in the nightshade family, concentrated most heavily in the leaves of tobacco (Nicotiana tabacum). It binds with high affinity to nicotinic acetylcholine receptors (nAChRs) throughout the central and peripheral nervous systems, producing a rapid and well-characterized cognitive signature — increased attention, faster reaction time, and modest working-memory improvement. The same mechanism that makes nicotine cognitively active also makes it one of the most addictive substances studied in humans. The U.S. Surgeon General has repeatedly concluded that nicotine is addictive in a manner and degree similar to heroin and cocaine, and that combusted tobacco use remains the leading preventable cause of disease and death in the United States. This page exists because nicotine has been studied as a cognitive enhancer in non-smoking populations (via patch or gum) and is occasionally discussed in the nootropic literature; it is presented here from a harm-reduction and scientific-literacy standpoint only. NootStack provides no affiliate links, product recommendations, or buying guides for nicotine and does not recommend its use as a nootropic.
Mechanism of Action
Nicotine is a potent agonist at nicotinic acetylcholine receptors (nAChRs) — pentameric ligand-gated ion channels distributed throughout the central and peripheral nervous system. In the brain, α4β2 nAChRs on dopaminergic neurons of the ventral tegmental area drive phasic dopamine release in the nucleus accumbens, which underlies both the attention-sharpening and the reinforcing (addictive) effects. α7 nAChRs in cortex and hippocampus contribute to the pro-cognitive effects on attention, working memory, and sensory gating. Nicotinic activation also releases acetylcholine, norepinephrine, serotonin, glutamate, and GABA in a region-specific manner. Chronic exposure upregulates nAChRs (a paradoxical consequence of desensitization), a neuroadaptation that underlies tolerance, withdrawal, and the characteristic craving cycle.
Benefits & Evidence
Attention & Sustained Vigilance
Heishman's 2010 meta-analysis of 41 studies found small-to-moderate improvements in fine motor performance, alerting attention, orienting attention, short-term episodic memory, and working memory in non-smoking adults given acute nicotine. This is the most-replicated cognitive finding in the nicotine literature.
Cognitive Support in Mild Cognitive Impairment
Newhouse 2012 — a 6-month double-blind RCT of transdermal nicotine (15mg/day) in 67 non-smoking MCI patients — found improvements in attention, memory, and psychomotor speed. This is one of few controlled trials of non-smoked nicotine in a cognitively vulnerable population.
Visuospatial Attention (Mechanism-Level Evidence)
Hahn 2007 (fMRI) showed nicotine enhances visuospatial attention partly by deactivating default-mode-network regions, consistent with a neurally specific attention-boosting mechanism rather than a generalized arousal effect.
Dosage & Timing
Not recommended as a nootropic — no dose is endorsed by NootStack
N/A — NootStack does not recommend any use frequency
N/A
0mg — 0mg
Note: Cognitive studies in non-smokers have commonly used 2mg gum or 7–21mg transdermal patches (Newhouse 2012 used 15mg/day patch). Even these low-dose, non-combusted delivery routes produce dependence in a substantial minority of users. If you are already a nicotine user considering a switch in delivery route for harm-reduction, this is a conversation to have with a physician, not a supplement stack decision. NootStack does not provide dose guidance for nicotine as a nootropic.
Safety Profile
Side Effects
- Addiction / physical dependence (the defining risk — can develop within days to weeks of regular use, including with non-combusted forms)
- Nausea, vomiting, dizziness, headache at acute exposure
- Elevated heart rate and blood pressure
- Insomnia and disrupted sleep architecture
- Skin irritation (patch)
- Oral/throat irritation, hiccups (gum, lozenge, pouch)
- Anxiety and irritability during withdrawal
- In combusted tobacco: dramatic long-term increases in cardiovascular disease, stroke, COPD, and cancer of the lung, throat, mouth, esophagus, pancreas, bladder, and others (attributable to combustion products, not nicotine itself)
- Impaired prefrontal cortical development when exposure occurs in adolescence
Interactions
- Caffeine, other stimulants (additive cardiovascular strain)
- Nicotine metabolism is induced by CYP1A2 substrates/inducers; clozapine, olanzapine, theophylline, and several other drugs have altered clearance in smokers
- Insulin and oral hypoglycemics (nicotine affects glucose regulation)
- Beta-blockers (altered hemodynamic response)
- SSRIs and MAOIs (caution; smoked tobacco contains MAO inhibitors separate from nicotine itself)
Contraindications
- Pregnancy — nicotine is a recognized developmental neurotoxin; no level is considered safe for fetal brain development
- Breastfeeding
- Adolescents and young adults under ~25 (ongoing prefrontal development; increased vulnerability to addiction and structural brain effects)
- History of nicotine or other substance-use disorder
- Unstable cardiovascular disease, recent myocardial infarction, uncontrolled hypertension, serious arrhythmia
- Active peptic ulcer (nicotine increases gastric acid)
References & Sources
Meta-analysis of the acute effects of nicotine and smoking on human performance
Heishman SJ, Kleykamp BA, Singleton EG
Psychopharmacology (2010)
Meta-analysis of 41 double-blind, placebo-controlled studies found nicotine significantly improved fine motor performance, alerting and orienting attention, short-term episodic memory, and working memory — with effects robust in non-smokers as well as abstinent smokers.
DOI: 10.1007/s00213-010-1848-1 ↗Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial
Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, et al.
Neurology (2012)
Six-month double-blind RCT in 67 non-smoking amnestic MCI patients: 15mg/day transdermal nicotine improved attention, memory, and psychomotor speed versus placebo, with no withdrawal reported at discontinuation.
DOI: 10.1212/WNL.0b013e31823efcbb ↗Cognitive Effects of Nicotine: Recent Progress
Valentine G, Sofuoglu M
Current Neuropharmacology (2018)
Review synthesizing modern evidence on nicotine's effects on attention, memory, and executive function — and the methodological challenges (withdrawal reversal) that have complicated earlier interpretations.
DOI: 10.2174/1570159X15666171103152136 ↗Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network
Hahn B, Ross TJ, Yang Y, Kim I, Huestis MA, Stein EA
The Journal of Neuroscience (2007)
fMRI study demonstrating nicotine-induced improvements in visuospatial attention are associated with suppression of default-mode-network activity, a neurally specific attention-enhancement mechanism.
DOI: 10.1523/JNEUROSCI.5129-06.2007 ↗Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization
Levin ED, McClernon FJ, Rezvani AH
Psychopharmacology (2006)
Comprehensive review of nicotinic receptor subtype contributions (α4β2, α7) to attention, working memory, and learning across species, establishing the mechanistic basis for nicotine's pro-cognitive effects.
DOI: 10.1007/s00213-005-0164-7 ↗